Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
The split will reduce outstanding common stock from approximately 4.77 million to 1.59 million shares.
Reverse Stock Split
1 for 3 reverse stock split to comply with Nasdaq listing rule.
Reduced Outstanding Shares
Reduction from 4.77 million to 1.59 million shares after the split.
Fractional Shares Handling
No fractional shares will be issued; cash will be given in lieu of fractional shares.
- Maintaining Nasdaq listing for credibility and visibility.
- Enhancing shareholder value through compliance with listing requirements.
The reverse stock split is a strategic move by Entero Therapeutics to ensure continued Nasdaq listing and improve shareholder value.